B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Conditions:   Pediatric Solid Tumor;   Osteosarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Ewing Sarcoma;   Wilms Tumor;   Adrenocortical Cancer;   Desmoplastic Small Round Cell Tumor;   Germ Cell Cancer;   Rhabdoid Tumor;   Clear Cell Sarcoma;   Hepatoblastoma;   Melanoma;   Carcinoma;   Malignant Peripheral Nerve Sheath Tumors;   Soft Tissue Sarcoma
Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MESNA;   Drug: B7-H3 CAR T cells
Sponsor:   St. Jude Children’s Research Hospital
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 6, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments